BioAtla Corp (BCAB) Net earnings per share growth forecast for next year

Corporate company logo of BioAtla (BCAB)

BioAtla, Inc. (BCAB) price action is independent of GDP, as demand for precision oncology therapy remains stable. Shifting analyst expectations for n+1 EPS growth visualize this market signal, where 0.00 determines the latest valuation metric. The business foundation rests on creating selective drugs for the target market, while production flexibility is ensured by outsourcing antibody manufacturing to external contract organizations.

BioAtla Corp (BCAB): Net earnings per share growth forecast for next year from 07/04/2022 to 09/06/2026

Summary analytical data breakdowns for BioAtla (BCAB)

- share price and consensus valuation forecast:
Stock Price BioAtla Inc|BCAB - Consensus Target
- market capitalization details:
Market Value BioAtla|BCAB - Total Enterprise Value
- company book value details:
Net Assets per Single Share BioAtla|BCAB - Company Book Value|Market Value to Book Value Ratio bioatla.com|BCAB - Company Assets
- issuer credit burden and liquidity indicators:
Total Debt to Capital BioAtla, Inc.|BCAB - Long-Term Indebtedness to Equity|Short-Term Debt to Equity Ratio BioAtla Inc|BCAB - Company Cumulative Debt|Debt to Book Value BioAtla|BCAB - Company Long-Term Loans and Borrowings|Company Current Liabilities BioAtla|Quick Ratio bioatla.com
- net income and valuation ratios data:
BCAB - Final Profit|Projected Future Earnings BioAtla, Inc.|BCAB - Market Cap to Earnings|Future Price to Earnings BioAtla Inc|BCAB - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple BioAtla|BCAB - Operating profit EBITDA|Earnings per share for the last twelve months BioAtla|BCAB - Earnings per one share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months bioatla.com|BCAB - Earnings per share growth rate in current year|Earnings growth forecast for next year BioAtla, Inc.
Fundamental company analysis:BioAtla, Inc.
Finished products of BioAtla Corp

This indicator provides a dynamic assessment of the expected change in earnings per share based on expert consensus forecasts. It measures the business growth vector, allowing investors to evaluate the risk of overpaying for an asset by comparing current expectations with historical data. For BioAtla, Inc. (BCAB), whose research in the US is protected by the humanitarian status of oncology, the consensus on the earnings per share change for the coming year reflects market optimism regarding the commercialization of biologics.

Competitor analysis for BioAtla, Inc.

INCY (Incyte Corp.) - Earnings growth forecast for next year|Expected earnings per share growth for next year HUTCHMED Corp (HCM)|Net earnings per share growth forecast for next year Nuvation Bio Inc. (NUVB)|DAWN - Expected net earnings per share growth next year|Net earnings per share growth forecast for next year Monopar Therapeutics Inc. MNPR|Inhibrx - Net earnings per share growth forecast for next year|IMAB - Net earnings per share growth forecast for next year|Expected net earnings per share growth next year Fennec|HRTX: Earnings growth forecast for next year|Net earnings per one share growth forecast for next year nuvectis.com NVCT|Expected earnings per share growth for next year CHRS|Expected net earnings per share growth next year Corbus Pharmaceuticals Holdings, Inc. CRBP|Expected earnings per share growth for next year CRDF (Cardiff Oncology, Inc.)|BYSI (BeyondSpring Inc) - Expected earnings per share trend next year|Lixte Biotechnology - Expected earnings per share growth for next year|Projected earnings per share increase next year CTXR (Citius Pharmaceuticals Inc.)|Cellectar Biosciences, Inc. - Earnings growth forecast for next year|Expected earnings per share trend next year BLRX (BioLineRx Ltd)|CANF: Earnings growth forecast for next year|Expected net earnings per share growth next year Aprea Therapeutics, Inc. (APRE)|Net earnings per share growth forecast for next year Kazia Therapeutics Ltd|SLXN: Expected earnings per share trend next year|Earnings growth forecast for next year NCNA|Earnings growth forecast for next year Chimerix Inc. (CMRX)|Net earnings per share growth forecast for next year Cyclacel Pharmaceuticals Inc. CYCC|GTHX (G1 Therapeutics Inc.) - Net earnings per share change forecast for next year|KRON: Expected earnings per share growth for next year|Expected net earnings per share growth next year kintara.com|ONCT: Earnings growth forecast for next year|PRTG (Portage Biotech Inc) - Net earnings per share growth forecast for next year